- Allergy Therapeutics announced positive clinical results of its dust mite allergy treatment .

The AM101 trial assessed the safety and tolerability of the company's Acarovac injection to treat dust mite allergies in 16 adult patients and achieved its primary endpoint as the formulation was well tolerated and safety profile satisfactory, the company said.

The trail tested the safety and tolerability of 7 injections of Acarovac MPL administered over 6-12 weeks each 1-2 weeks apart.

The results also showed 'significant improvement' from baseline in patients' total symptom scores following a nasal provocation test after 12 weeks, and 'significant increases' in immunoglobulin markers and reduction in IL-4 were observed.

The secondary endpoints of the trail included the effect of treatment on response to nasal provocation test (NPT), immunological parameters including immunoglobulins and patients' satisfaction with the treatment.

'The success of our clinical trial in house dust mite-induced allergic rhinitis is encouraging news for the many patients who continue to suffer with the symptoms caused by house dust mite allergy, and supports our ambition to provide a global therapy for the important US, China and EU markets,' said Manuel Llobet, Chief Executive Officer of Allergy Therapeutic.

'Based on the unique triple-combination of our allergoids, and the adjuvant system MPL and MCT we believe Acarovac MPL could build on our success in dust mite immunotherapy and we look forward to progressing towards phase II clinical studies.'

At 9:25am: [LON:AGY] Allergy Therapeutics PLC share price was +0.25p at 12.75p

Story provided by